

CURRICULUM VITAE

Dr. Fabio Benedetti

Personal data

Date of birth:

Place of birth:

Citizenship : Italian

Work address: Azienda Ospedaliera Universitaria Integrata di Verona, Sezione di Ematologia e Centro Trapianto Midollo Osseo, Dipartimento di Medicina - Divisione di Ematologia

Policlinico G.B. Rossi

Piazzale L.A. Scuro, 10

37134, Verona - Italy

phone: 045 8124647, fax: 045 8027488

E-mail: fabio.benedetti@univr.it

Education

1981 Medical Doctor degree, University of Padova, Padova, Italy

1984 National Board of Hematology, University of Verona, Verona, Italy

1990 National Board of Internal Medicine, University of Verona, Verona, Italy

Medical Licence: Verona - Italy, 1981: number 5385

Professional Record, Main work and Experience in the Research Area

- Hematology training, Department of Hematology, University of Verona, Italy 1981-1984
- Internal Medicine Training, Department of Internal Medicine, University of Verona, Italy 1985-1990
- Staff member, Dept. of Hematology and Bone Marrow Transplantation, University of Verona - Italy, 1987- present
- Fellowship on Bone Marrow Transplant, "Istituto Seragnoli, University of Bologna -Italy, 1984
- Fellowship on Bone Marrow Transplant, FHCRC, Seattle - USA, 1991-1992
- Fellowship on Minimal Residual Disease at the Bone Marrow Transplantation Unit, Dana-Farber Cancer Institute, Harvard Medical School, Boston, USA, 1994
- Head, Bone Marrow Transplant Program, Department of Hematology, University of Verona, Italy 1999- present

Publications

- 85 original contributions to international journals or reviews and more than 180 abstracts

Last GCP training: "The Global Health Network" ICH GOOD CLINICAL PRACTICE E6 (R2) 04/03/2019

GCP clinical trials:

1996-2012:

- Participation as Principal Investigator in 1 Clinical Trials concerned phase II in Follicular Lymphoma;
- Participation as Principal Investigator in 1 Clinical Trials concerned phase II in Mantle Cell Lymphoma;
- Participation as Principal Investigator in 1 Clinical Trials concerned phase II Peripheral T cell non Hodgkin Lymphoma (PTCL);

- Participation as Principal Investigator in 1 Clinical Trials concerned phase III in Large B cell Lymphoma.

2013 - present:

- Participation as Principal Investigator in 4 Clinical Trials concerned phase II-III in Peripheral T Cell Lymphoma;
- Participation as Principal Investigator in 2 Clinical Trials concerned phase II-III in Mantle Cell Lymphoma;
- Participation as Co-Investigator in 1 Clinical Trials concerned phase II in the treatment of CMV infection in hematopoietic stem cell transplant recipient;
- Participation as Principal Investigator in 2 Clinical Trials concerned phase II-III in GVHD treatment;
- Participation as Principal Investigator in 1 Clinical Trials concerned phase III in CD20 positive B cell Non Hodgkin Lymphoma (NHL);
- Participation as Principal Investigator in 1 Clinical Trials concerned phase III in relapsed/refractory Follicular Lymphoma;
- Participation as Principal Investigator in 1 Clinical Trials concerned phase I in Diffuse large B Cell Lymphoma;
- Participation as Principal Investigator in 1 Clinical Trials concerned phase III in High Risk Acute Leukemia;

Selected Papers and books:

Benedetti F. Trapianto di Midollo Osseo. in " Nuovo Roversi", Edizioni Ariete Salute , Milano 1998, pag. 300-309.

Scambi C, La Verde V, De Franceschi L, Barausse G, Poli F, **Benedetti F**, Sorio M, Deriu F, Roncada P, Bortolami O, Turrini F, Caramaschi P, Stranieri C, Bambara LM, Biasi D. Comparative proteomic analysis of serum from patients with systemic sclerosis and sclerodermatous GVHD. Evidence of defective function of factor H. PLoS One. 2010 Aug 13;5(8):e12162.

C Tarella, R Passera, M Magni, **F Benedetti**, A Rossi, A Gueli, C Patti, G Parvis, F Ciceri, A Gallamini, S Cortellazzo, V Zoli, P Corradini, A Corrobbio, A Mulè, M Bosa, A Barbi, M Di Nicola, M Sorio, D Caracciolo, A Gianni and A Rambaldi. Risk factors for the development of secondary malignancy after high-dose chemotherapy and autografo, with or without Rituximab: a 20-year retrospective follow-up study in patients with lymphoma. J Clin Oncol. 2011 Mar 1; 29(7): 814-24.

Todeschini G, Bonifacio M, Tecchio C, Dalceggio D, **Benedetti F**, Gabbas A, Pizzolo G A preliminary experience with the HyperCHiDAM Verona intensive chemotherapy regimen in heavily pretreated refractory Hodgkin's lymphoma. Hematol Oncol. 2011 Sep; 29(3): 151-3

Bassetti M, Aversa F, Ballerini F, **Benedetti F**, Busca A, Cascavilla N, Concia E, Tendas A, Di Raimondo F, Mazza P, Nosari AM, Rossi G. Amphotericin B lipid complex in the management of invasive fungal infections in immunocompromised patients. Clin Drug Investig. 2011 Nov 1; 31(11):745-58

Rambaldi A, Bacigalupo A, Fanin R, Ciceri F, Bonifazi F, Falda M, Lambertenghi-Deliliers G, **Benedetti F**, Bruno B, Corradini P, Alessandrino PE, Iacopino P, Arcese W, Scimè R, Raimondi R, Sica S, Castagna L, Lamparelli T, Oneto R, Lombardini L, Pollichieni S, Algarotti A, Carobbio A, Sacchi N, Bosi A. Outcome of patients activating an unrelated donor search: the impact of transplant with reduced intensity conditioning in a large cohort of consecutive high-risk patients. Leukemia. 2012 Aug; 26(8): 1779-85

Dodero A, Spina F, Narni F, Patriarca F, Cavattoni I, **Benedetti F**, Ciceri F, Baronciani D, Scimè R, Pogliani E, Rambaldi A, Bonifazi F, Dalto S, Bruno B, Corradini P. Allogeneic transplantation following a reduced-intensity conditioning regimen in relapsed/refractory

peripheral T-cell lymphomas: long-term remissions and response to donor lymphocyte infusions support the role of a graft-versus-lymphoma effect. *Leukemia*. 2012, Mar; 26(3): 520-6.

Magni M, Di Nicola M, Patti C, Scimè R, Mulè A, Rambaldi A, Intermesoli T, Viero P, Tarella C, Gueli A, Bergui L, Trentin L, Barzan A, **Benedetti F**, Ambrosetti A, Di Raimondo F, Chiarenza A, Parvis G, Billio A, Attolico I, Olivieri A, Montanari M, Carlo-Stella C, Matteucci P, Devizzi L, Guidetti A, Viviani S, Valagussa P, Gianni AM. Results of a randomized trial comparing high-dose chemotherapy plus Auto-SCT and R-FC in CLL at diagnosis. *Bone Marrow Transplantation*. 2014 Apr;49(4):485-91. doi: 10.1038/bmt.2013.214. Epub 2014 Jan 20.

Corradini P, Vitolo U, Rambaldi A, Miceli R, Patriarca F, Gallamini A, Olivieri A, **Benedetti F**, Todeschini G, Rossi G, Salvi F, Bruno B, Baldini L, Ferreri A, Patti C, Tarella C, Pileri S, Doderio A. Intensified chemo-immunotherapy with or without stem cell transplantation in newly diagnosed patients with peripheral T-cell lymphoma. *Leukemia*. 2014 Sep;28(9):1885-91. doi: 10.1038/leu.2014.79. Epub 2014 Feb 20.

Mimiola E, Marini O, Perbellini O, Micheletti A, Vermi W, Lonardi S, Costantini C, Meneghelli E, Andreini A, Bonetto C, Vassanelli A, Cantini M, Zoratti E, Massi D, Zamo' A, Leso A, Quaresmini G, **Benedetti F**, Pizzolo G, Cassatella MA, Tecchio C. Rapid reconstitution of functionally active 6-sulfoLacNAc(+) dendritic cells (sLanDCs) of donor origin following allogeneic haematopoietic stem cell transplant. *Clin Exp Immunol*. 2014 Oct;178(1):129-41. doi: 10.1111/cei.12387.

Cortelazzo S, Tarella C, Gianni AM, Ladetto M, Barbui AM, Rossi A, Gritti G, Corradini P, Di Nicola M, Patti C, Mulè A, Zanni M, Zoli V, Billio A, Piccin A, Negri G, Castellino C, Di Raimondo F, Ferreri AJ, **Benedetti F**, La Nasa G, Gini G, Trentin L, Frezzato M, Flenghi L, Falorio S, Chilosi M, Bruna R, Tabanelli V, Pileri S, Masciulli A, Delaini F, Boschini C, Rambaldi A. Randomized Trial Comparing R-CHOP Versus High-Dose Sequential Chemotherapy in High-Risk Patients With Diffuse Large B-Cell Lymphomas. *JCO*. 2016 Nov 20;34(33):4015-4022. doi: 10.1200/JCO.2016.67.2980. Epub 2016 Oct 31.

Nicolaus Kröger, M.D., Carlos Solano, M.D., Christine Wolschke, M.D., Giuseppe Bandini, M.D., Francesca Patriarca, M.D., Massimo Pini, M.D., Arnon Nagler, M.D., Carmine Selleri, M.D., Antonio Risitano, M.D., Ph.D., Giuseppe Messina, M.D., Wolfgang Bethge, M.D., Jaime Pérez de Oteiza, M.D., Rafael Duarte, M.D., Angelo Michele Carella, M.D., Michele Cimminiello, M.D., Stefano Guidi, M.D., Jürgen Finke, M.D., Nicola Mordini, M.D., Christelle Ferra, M.D., Jorge Sierra, M.D., Ph.D., Domenico Russo, M.D., Mario Petrini, M.D., Giuseppe Milone, M.D., **Fabio Benedetti, M.D.**, Marion Heinzlmann, Domenico Pastore, M.D., Manuel Jurado, M.D., Elisabetta Terruzzi, M.D., Franco Narni, M.D., Andreas Völz, Ph.D., Francis Ayuk, M.D., Tapani Ruutu, M.D., and Francesca Bonifazi, M.D. Antilymphocyte Globulin for Prevention of Chronic Graft-versus-Host Disease, *NEJM*, January, 2016, 34-53

Michele Gottardi, Federico Mosna, Sergio de Angeli, Cristina Papayannidis, Anna Candoni, Marino Clavio, Cristina Tecchio, Andrea Piccin, Marta Campo dell'Orto, **Fabio Benedetti**, Giovanni Martinelli, Filippo Gerlinzoni. Clinical and experimental efficacy of Gemtuzumab Ozogamicin in Core Binding Factor Acute Myeloid Leukemia. *Hematology Reports*, 2017; 9:7028, 87-90

Bruna R, **Benedetti F**, Boccomini C, Patti C, Barbui AM, Pulsoni A, Musso M, Liberati AM, Gini G, Castellino C, Rossini F, Ciceri F, Rota-Scalabrini D, Stelitano C, Di Raimondo F, Tucci A, Devizzi L, Zoli V, Zallio F, Narni F, Dondi A, Parvis G, Semenzato G, Lanza F, Perrone T, Angrilli F, Billio A, Gueli A, Mantoan B, Rambaldi A, Gianni AM, Corradini P, Passera R, Ladetto M, Tarella C. Prolonged survival in the absence of disease-recurrence in advanced-stage follicular lymphoma following chemo-immunotherapy: 13-year update of the prospective, multicenter randomized GITMO-III trial. *Haematologica*. 2019 Nov;104(11):2241-224

Fabio Benedetti, MD



Verano 14/12/2021